Diabetic wounds, often multifactorial and affecting multiple organs, pose substantial challenges to patient well-being, drawing significant interest in biomedical engineering. The demanding wound microenvironment, marked by heightened glucose levels, local exudate, and bacterial infections, emphasizes the pressing demand for advanced wound dressings to meet escalating clinical needs. Herein, a Janus wound dressing with an integration of an antimicrobial hydrophobic nanofiber layer and a 3D hydrophilic sponge was designed and prepared to manage and utilize wound exudate. The hydrophobic layer skillfully combined electrospun poly(ε-caprolactone) (PCL) nanofiber membranes (ENMs) and metal-organic frameworks (MOFs) with peroxidase-like properties by solvent etching, and glucose oxidase (GOx) was grafted through ligand interaction. GOx acts to consume glucose while modulating pH, thus suitable pH and self-supplied HO were able to activate the catalytic activity of MOFs to generate OH. Additionally, hydrophilic 3D sponges are constructed using gas foaming technology, which are tactfully combined with hydrophobic ENMs to form a Janus structure, which can transport exudate through the antimicrobial layer to the sponge layer, while sufficient glucose contact with GOx enhances the antimicrobial properties of the designed Janus wound dressing. Experimental results demonstrate the effectiveness of the cascade effect of GOx@PCL/MOF ENMs, ultimately releasing reactive oxygen species and exhibiting robust antibacterial properties. In vivo animal experiments reveal the ability of the Janus wound dressing to mitigate methicillin-resistant (MRSA) infections in the early stages, thereby expediting the wound healing process. In vivo animal study, the Janus wound dressing achieved a healing rate of 54% on day 3. Our findings underscore the substantial potential of the Janus wound dressings in promoting the healing of chronic diabetic wounds.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsami.4c18298 | DOI Listing |
Br J Dermatol
December 2024
The Pennsylvania State University College of Medicine, Department of Dermatology, Hershey, PA, USA.
Background: Therapeutic options for mild hidradenitis suppurativa (HS) represent a significant gap in the current treatment landscape, with no FDA approved therapies for early stage HS. Topical JAnus Kinase inhibitors (JAKi) are a compelling option due to the known upregulation of inflammatory JAK signaling in HS lesions and the recent success of systemic JAKi for moderate to severe HS.
Objectives: This is a pilot, single-site, open-label, prospective 24-week clinical trial with topical ruxolitinib (NCT04414514).
ACS Appl Mater Interfaces
December 2024
Key Laboratory of Textile Science & Technology, Ministry of Education, Donghua University, Shanghai 201620, China.
Small
December 2024
Shanghai Engineering Research Center of Tooth Restoration and Regeneration & Tongji Research Institute of Stomatology & Department of Prosthodontics, Shanghai Tongji Stomatological Hospital and Dental School, Tongji University, Shanghai, 200072, China.
Skin wound healing is often hindered by disrupted mitochondrial homeostasis and imbalanced macrophage glucose metabolism, posing a critical challenge to improve patient outcomes. Developing new wound healing dressings capable of effectively regulating macrophage immune-metabolic functions remains a pressing issue. Herein, a highly adhesive polyethylene glycol (PEG) hydrogel loaded with the Janus kinase 1 (JAK1) inhibitor Filgotinib (Fil@GEL) is prepared to modulate macrophage metabolic reprogramming and restore normal mitochondrial function.
View Article and Find Full Text PDFOncol Lett
February 2025
Department of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, P.R. China.
Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide, necessitating new treatment approaches with minimal side effects. In the present study, the potential of Bergapten (5-methoxypsoralen), a natural furanocoumarin compound, as a therapeutic agent against NSCLC was investigated by using network pharmacology, molecular docking and validation. Bergapten targets were identified using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and SwissTarget databases, whilst lung cancer-related targets were sourced from GeneCards and DisGeNET.
View Article and Find Full Text PDFACS Appl Bio Mater
December 2024
Caspian Faculty of Engineering, College of Engineering, University of Tehran, Rezvanshar, Guilan 43861-91836, Iran.
A promising approach for wound treatment is using multilayer wound dressings that offer multifunctional properties. In this study, a bilayered electrospun/hydrogel gelatin-based scaffold integrated with honey and curcumin was developed to treat wounds under an in vivo study. The first layer consisted of an enzymatic cross-linked gelatin hydrogel containing honey and curcumin, which gelatin/PCL nanofibers reinforced.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!